Now Reading: Marksans Pharma Q1 profit jumps 43.6%; broader market trends mixed
-
01
Marksans Pharma Q1 profit jumps 43.6%; broader market trends mixed
Marksans Pharma Q1 profit jumps 43.6%; broader market trends mixed
Marksans Pharma reported a 43.6% year-on-year rise in net profit for Q1FY27, driven by a 74.7% jump in UK and Europe revenues to Rs 356 crore and 15.1% growth in US revenues…
The Story in Brief
Marksans Pharma reported a 43.6% year-on-year rise in net profit for Q1FY27, driven by a 74.7% jump in UK and Europe revenues to Rs 356 crore and 15.1% growth in US revenues to Rs 377 crore. The company's consolidated PAT rose to Rs 143 crore from Rs 99.5 crore a year ago, according to the businessline report.
Meanwhile, Patel Retail saw PAT rise to Rs 9.51 crore from Rs 6.92 crore, while Mindteck's net profit fell to Rs 8.36 crore from Rs 10.16 crore. Hi-Tech Pipes PAT slipped to Rs 15.16 crore versus Rs 16 crore, and Innovision posted a net loss of Rs 6.7 crore. The Sensex fell 597 points to 77,557 and Nifty dropped 188 points to 24,283 on August 12.
The Indian Opinion
The 'all-is-well' narrative peddled by some market cheerleaders ignores the mixed reality of this Q1 season. Pharma and retail firms like Marksans and Patel Retail show healthy demand, but Mindteck's and Hi-Tech Pipes' profit dips, and Innovision's outright loss, reveal a patchy recovery. Corporate earnings are a mosaic, not a single-colour board. Investors should watch if the Nifty's 188-point drop today is a blip or the start of a trend reflecting these divergent results.
Sources (2): thehindubusinessline.com, thehindubusinessline.com (2)
This story was synthesised by AI from the 2 sources linked above.
Updated: this story now draws on 2 sources.
